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Summary
Objective: To determine the association between changes in serum levels of cartilage oligomeric matrix protein (COMP) and serum
N-telopeptide crosslinks (NTX) over a 6-year interval with the development and progression of radiographically apparent hip osteoarthritis
(RHOA) in a community sample of elderly women over 8.3 years of follow-up.
Methods: Pelvic radiographs were obtained a mean of 8.3 years apart in Caucasian women 65 years of age enrolled in the Study of Oste-
oporotic Fractures. From a cohort of 5928 subjects, we randomly sampled study subjects (w170 per group) to perform two nested casee
control studies, one of RHOA incidence and the other of RHOA progression. Baseline and year 6 serum COMP and serum NTX levels
were measured by enzyme linked immunosorbent assay in duplicate and percentage change in serum levels was calculated. Odds ratios
(ORs) and 95% conﬁdence intervals (CIs) for 1 standard deviation (SD) change in the serum COMP and NTX level differences were calculated
using logistic regression analysis and used to predict the development or progression of RHOA, adjusting for potential covariates.
Results: The percentage change in the level of serum COMP from baseline to year 6 was found to be a risk factor for the development of
incident RHOA [adjusted OR of 1.58 per 1 SD increase (95% CI: 1.19e2.09)], and reduction of progression of RHOA [adjusted OR of
0.74 per 1 SD increase (95% CI: 0.58e0.96)]. Quartile analysis of serum COMP changes revealed that the three highest quartiles of change
in serum COMP were associated with (1) a ﬁve-fold greater risk of developing incident RHOA [adjusted OR¼ 5.42 (95% CI: 2.80e10.60)], and
(2) a 50% decreased risk of developing progression of RHOA [adjusted OR¼ 0.48 (95% CI: 0.30e0.80)]. No signiﬁcant association was found
between changes in serum NTX levels from baseline to year 6 with either incident RHOA or the progression of existing RHOA.
Conclusion: Measurement of serum COMP at two distinct timepoints may be a method of identifying patients at risk for developing incident
RHOA and those with baseline RHOA that will not rapidly progress.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common disease and a common
cause of disability in the elderly. Currently, over 230,000
people in the USA will undergo either hip or knee joint
replacement annually for advanced OA1.
There are no widely used and reliable biomarkers for pre-
dicting who is at risk of developing hip or knee OA, and no*Address correspondence and reprint requests to: Dr Nancy E.
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566validated non-radiologic methods for monitoring progression
of OA. While several validated methods exist for grading
severity of existing OA on standard radiographs, these
methods can be insensitive to early changes of cartilage
and bone metabolism.
Recently, several groups have evaluated the use of serial
measurements of serum and urine biomarkers in OA to
gauge severity and progression of disease with promising
results2e4. Serial time measurements of biomarkers have
also been used in attempts to evaluate response to potential
disease modifying OA drugs (DMOADs)5. Thus, by evaluat-
ing potential markers of bone and cartilage turnover over two
or more points in time, it may be possible to recognize active
attempts at cartilage repair while they are occurring; this
measurement, in turn, may provide a window of opportunity
567Osteoarthritis and Cartilage Vol. 16, No. 5for preventing worsening of joint degeneration and a means
of measuring tissue response to potential DMOADs.
We recently reported that baseline measurements of the
serum markers cartilage oligomeric matrix protein (COMP)
and N-telopeptide crosslinks (NTX) of type I collagen
were modest risk factors associated with the development
of incident radiographic hip osteoarthritis (RHOA)6. Since
there have been reports that serial measurements may be
more informative regarding disease progression2e4, the
purpose of this study was to investigate whether serial mea-
surements of a potential biomarker are better able to predict
patients at risk of incident or progressive OA than the base-
line measurements alone.Patients and methodsSTUDY POPULATIONPatients were white women 65 years of age at baseline who were
enrolled in the Study of Osteoporotic Fractures (SOF), a cohort whose char-
acteristics have been described in our previous paper6. Participants were
recruited between September 1986 and October 1988 from population-
based listings in four areas of the USA7. Non-white women were excluded
from the original cohort because of their low incidence of hip fracture, as
were women who were non-ambulatory or who had undergone bilateral
hip replacement7. In addition, women with radiographically conﬁrmed rheu-
matoid arthritis, Paget’s disease, or hip fracture at baseline were excluded
from this analysis.
Two nested caseecontrol studies were performed, similar to the methods
reported previously6. From the SOF cohort, 5928 subjects with supine pelvic
X-rays at baseline and 8.3 years apart were identiﬁed. Of these subjects, 677
subjects had COMP and NTX measured on serum collected at baseline and
at year 6. These subjects were assigned to one of the two nested casee
control studies, one focusing on RHOA incidence (n¼ 336) and the other
on RHOA progression (n¼ 341) (see Fig. 1).RADIOGRAPHY AND INTERPRETATIONAt the baseline and follow-up visits (average 8.3 years follow-up time),
supine anteroposterior radiographs of the pelvis were obtained using a stan-
dard protocol7. Radiographs were assessed for ﬁve individual radiographic
features (IRFs) of hip OA (joint space narrowing (JSN), osteophyte forma-
tion, subchondral sclerosis, cysts, and deformity) using atlas photographs
to improve the reliability of the readings8,9. Minimum joint space (MJS)
was measured using published methods10. The methods for radiographic
interpretation have been previously published7,11,12.
Radiograph pairs were initially read and measured by a primary reader
(NEL) side-by-side with the reader blinded to the order by masking identify-
ing information and randomly assigning the order of ﬁlms. Radiograph pairs
with either deﬁnite osteophytes or deﬁnite narrowing (severity score> 2) in
any location on the initial reading were jointly evaluated by two readers toSTUDY GRO
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Fig. 1. Study groureach consensus scoring. A total of 21% of the ﬁlm pairs underwent a con-
sensus reading. Inter-rater reliability for the radiographic readings evaluated
from a random sample of 178 pairs was good to excellent: for MJS< 1.5,
kappa¼ 0.95; for deﬁnite JSN, kappa¼ 0.91; and for deﬁnite osteophytes,
kappa¼ 0.717,11,12.DEFINITIONS OF RHOA AND RADIOGRAPHIC PROGRESSIONThe deﬁnitions of RHOA and radiographic progression that were used
have been previously described6,11,12. A summary grade of 0e4, modiﬁed
from Croft, was assigned to each hip based on IRFs. Grade 2 hips required
the presence of either deﬁnite (severity grade 2) JSN or osteophytes plus
at least one other feature (cysts or subchondral sclerosis). Grade 3 hips
required the presence of three of the following features: (1) deﬁnite osteo-
phytes, and (2) deﬁnite JSN, plus (3) either cysts or sclerosis. Grade 4
hips met the criteria for grade 3, and had femoral head deformity present.
Hips were considered to have baseline radiographic ﬁndings of hip OA if
any of the following three ﬁndings were present: (1) a summary grade 2, (2)
JSN severity grade 2 superolaterally or severity grade 3 superomedially,
or (3) deﬁnite osteophytes in any location and deﬁnite JSN in any location.
For this analysis, hips were divided into those with and without baseline ﬁnd-
ings of RHOA. Those without baseline RHOA were eligible to develop RHOA
at the follow-up visit. Hips with baseline RHOA were eligible for progression
at the follow-up visit. A hip was deﬁned as having developed OA (incident
disease) if any of the above three ﬁndings were present in the 8.3-year fol-
low-up radiograph in a hip without any radiographic features of OA at the
baseline. A hip was deﬁned as having progressed radiographically if any
of the following occurred between baseline and follow-up: (1) a decrease
in MJS of 0.5 mm, (2) an increase of one or more in the summary grade,
(3) an increase of 2 or more in total osteophyte score, or (4) total hip replace-
ment for OA between baseline and follow-up which was assessed by radiog-
raphy and review of the medical records.BIOCHEMICAL MEASUREMENTSBaseline and year 6 serum levels of COMP and NTX were measured in
duplicate on fasting serum samples. Serum COMP was measured with
a commercial enzyme linked immunosorbent assay (ELISA) kit (Anamar
Medical, Lund, Sweden) which utilized two mouse monoclonal antibodies
(12e11 and 6e8) directed against separate antigenic determinants on the
human COMP molecule. Methods of calibration and correlation with other re-
ported results have also been previously published6. Serum NTX was also
measured, using a commercially available ELISA kit (Osteomark, Princeton,
NJ, USA) that used a horseradish-peroxidase labeled monoclonal antibody
to NTX. The mean intra-assay coefﬁcient of variation for both assays was
5.02%. We previously published baseline results of COMP and NTX and
the development and progression of RHOA6. Approximately 20% of the sub-
jects from the previous study did not have serum samples at visit 4 (year 6)
and a small number of subjects no longer had a serum sample at the base-
line visit. Therefore, the study subject samples analyzed in this study were
somewhat different from the initial report. However, all available serum sam-
ples were re-analyzed and there was a correlation of nearly 90% between
the initial and follow-up COMP samples assayed.UPS
um COMP and NTX
 of radiographs 
Stable RHOA
(N= 173) 
Progressive RHOA
(N= 168) 
RHOA Progression Study
(N= 341)
p selection.
568 R. K. Chaganti et al.: Change in serum measurements of COMPSTATISTICAL ANALYSESComparison of baseline characteristics between cases and controls in the
incidence and progression studies was done using the chi-squared (dichot-
omous variables) or t test (continuous variables) analyses. We calculated
the percentage change between the two timepoints (baseline and after 6
years) for serum COMP and NTX, and performed logistic regression to
assess the odds ratio (OR) and 95% conﬁdence interval (CI) for incidence
and progression of RHOA per standard deviation (SD) of percentage and
absolute changes. Analyses were adjusted for the following covariates:
age, weight, height, hip pain, estrogen use, vitamin D use, and femoral
neck bone mineral density (BMD).ResultsSTUDY SUBJECT CHARACTERISTICSTable I shows the baseline characteristics for the sub-
jects in the two nested caseecontrol studies. In general,
the case and control subjects in both the incidence and
progression studies were not different. For the RHOA inci-
dence study, subjects in both groups were similar except
that subjects with incident RHOA were older. In the progres-
sion study, the baseline subject characteristics were also
similar except that subjects were taller in the RHOA
progression group (see Table I).CHANGE IN SERUM LEVELS OF COMP FROM BASELINE TO
VISIT 4 AND THE ASSOCIATION OF INCIDENT AND
PROGRESSIVE RHOAIncidence study
The mean percentage change in serum COMP levels
was nearly four times greater in the incident RHOA group
compared to the control group that did not develop
RHOA, though this difference was not statistically signiﬁ-
cant (Table II). There was a 58% increase in risk of incident
RHOA per 1 SD increase in change of COMP [age-adjusted
OR¼ 1.60 (95% CI: 1.22e2.09); adjusted OR¼ 1.58 (95%
CI: 1.19e2.09)] (Table II). Results remained similar after
adjusting for baseline serum COMP level [adjusted OR¼
1.66 (95% CI: 1.20e2.30)].
Progression study
The mean percentage change in serum COMP was 61%
more in those that had stable RHOA compared to thoseTable
Baseline characteristics of study subjects for the incid
Incidenc
No RHOA
(n¼ 169)*
Age (years) (meanSD) 69.6 3.7
Weight (kg) (meanSD) 67.5 11.2
Height (cm) (meanSD) 159.4 5.6
Hip pain (% positive) 58 (35%)
Estrogen use (% positive) 24 (14%)
Vitamin D use (% positive) 83 (51%)
Femoral neck BMD (g/cm2) (meanSD) 0.66 0.10
Baseline serum COMP (u/L) (meanSD) 11.06 3.32
Visit 4 serum COMP (u/L) (meanSD) 10.78 2.98
Baseline serum NTX (nM BCE) (meanSD) 20.29 8.97
Visit 4 serum COMP (nM BCE) (mean SD) 19.54 5.66
*Number of subjects () represents all subjects with baseline characte
u/L, units per liter.
yP< 0.05 vs subjects without RHOA.
zP< 0.005 vs subjects with stable RHOA.who had RHOA progression, though this change did not
reach a level of statistical signiﬁcance. The odds of progres-
sion were reduced 26% per 1 SD increase in COMP [age-
adjusted OR¼ 0.79 (95% CI: 0.62e1.00); adjusted
OR¼ 0.74 (95% CI: 0.58e0.96)] (Table II). Results were
not different after additional adjustment for baseline serum
COMP levels [adjusted OR¼ 0.69 (95% CI: 0.51e0.94)]
and baseline RHOA severity [adjusted OR¼ 0.73 (95%
CI: 0.56e0.96)].
Quartile analysis in incidence and progression studies
The risk of incident RHOA increased with an increasing
change in COMP with a greater than seven-fold risk of de-
veloping RHOA in the highest quartile of change compared
to the ﬁrst quartile (P-value for trend< 0.0001) (Fig. 2).
When the change in serum COMP was combined for quar-
tiles 2e4 and compared to the ﬁrst quartile, the risk of inci-
dent RHOA was ﬁve-fold greater [adjusted OR¼ 5.42 (95%
CI: 2.80e10.60)]. The risk of progression of RHOA de-
creased with an increasing change in COMP from baseline
to visit 4, and this risk was 52% lower in the highest three
quartiles of change in COMP compared to the ﬁrst quartile
[adjusted OR¼ 0.48, (95% CI: 0.30e0.90)]. No differences
were found after adjustment including baseline serum
COMP level.CHANGE IN SERUM LEVELS OF NTX FROM BASELINE TO
VISIT 4 AND THE ASSOCIATION OF INCIDENT AND
PROGRESSIVE RHOAThere was no signiﬁcant association between percent-
age change in serum NTX and the development of
RHOA or worsening of baseline RHOA. The odds of
incident and progressive RHOA per 1 SD increase in
serum NTX change over 6 years were 1.05 (95% CI:
0.81e1.36) and 0.93 (95% CI¼ 0.73e1.19), respectively.
Results were not different in the progression group, after
adjusting for baseline RHOA severity [OR¼ 0.94 (95%
CI: 0.73e1.21)]. Similar results were observed in the
quartile analysis for incident RHOA [adjusted OR for fourth
vs ﬁrst quartile¼ 1.06 (95% CI: 0.52e2.20)], and progres-
sive RHOA [adjusted OR for fourth vs ﬁrst quartile¼ 0.87
(95% CI: 0.40e1.70)].I
ence RHOA and the progression RHOA studies
e study Progression study
Incident RHOA
(n¼ 167)*
Stable RHOA
(n¼ 173)*
Progression of
RHOA (n¼ 168)*
70.8 4.6y 71.8 5.5 72.2 5.5
67.4 12.3 67.2 11.4 68.3 12.5
159.9 6.1 157.7 6.1 160.0 6.6z
57 (35%) 64 (37%) 79 (47%)
24 (14%) 16 (9%) 26 (16%)
75 (46%) 87 (51%) 82 (50%)
0.67 0.11 0.65 0.11 0.70 0.13
10.55 2.93 10.66 3.21 11.17 3.60
12.27 3.73 11.60 3.54 11.08 3.58
20.52 7.98 20.68 7.29 20.89 7.24
20.95 7.86 20.43 7.62 20.34 6.47
ristics and covariates collected. BCE, bone collagen equivalents;
Table II
Association of percentage change in serum levels of COMP and NTX with incidence and progression of RHOA per 1 SD increase
% Change in serum COMP Adjusted OR* (95% CI) % Change in serum NTX Adjusted OR* (95% CI)
Incidence study
No RHOA 4.0 37.6 Referent group 9.0 45.1 Referent group
Incident RHOA 19.2 31.1 1.58 (1.19e2.09) 11.9 44.2 1.05 (0.81e1.36)
Progression study
Stable RHOA 13.5 34.1 Referent group 8.9 48.6 Referent group
Progression of RHOA 5.3 36.7 0.74 (0.58e0.96) 6.9 44.6 0.93 (0.73e1.19)
*Adjusted for age, weight, height, estrogen use, hip pain, vitamin D use, and femoral neck BMD.
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We found a higher percentage increase in serum COMP
from baseline to year 6 is a risk factor for the development
of incident RHOA but not for progression of RHOA in a com-
munity sample of elderly Caucasian women. A stratiﬁed
analysis found that the three highest quartiles of change
in serum COMP were associated with (1) a ﬁve-fold greater
risk of developing incident RHOA per 1 SD of increase and
(2) a 50% decreased risk of progression of RHOA per 1 SD
increase in COMP.
COMP itself is a pentameric glycoprotein of the thrombo-
spondin family that is found predominantly in articular carti-
lage, but also in other tissues such as tendons and
synovium13,14. Changes in serum COMP are believed to re-
ﬂect changes in cartilage breakdown. Animal studies of OA
support this hypothesis: in studies of transgenic mice with
impaired collagen type II production, a transient upregula-
tion of serum COMP mRNA correlated temporally with the
onset of histological cartilage degeneration15. In pediatric
studies of patients with active juvenile idiopathic arthritis,
periods of pronounced growth plate impairment and de-
creased cartilage turnover were associated with decreased
serum COMP levels, compared to healthy controls16.
Attempts to correlate serum COMP levels with the devel-
opment and progression of RHOA must take into account
the complex pathogenesis of OA and the non-linear timeline
in which tissue destruction occurs. Altered joint biomechan-
ics and/or focal injury can lead to repeated articular carti-
lage insult and attempts at regeneration, which may
dominate in the pre-radiologic stage17,18. Metabolically
active cartilage in early OA can undergo multiple attempts
at repair, which in turn are associated with increased
levels of serum COMP. This phase of OA can also be0
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Fig. 2. Percentage change in serum COMP by quartiles and asso-
ciation with incident RHOA. *Adjusted for the following covariates:
age, weight, hip pain, estrogen use, vitamin D use, and femoral
neck BMD (P-value for trend <0.0001).accompanied by synovial inﬂammation, another tissue
source of elevated serum COMP19,20. As repeated insult
to the joint occurs, OA can become more established, and
continued loss of articular cartilage may outpace attempts
at repair, leading the remaining cartilage to be less metabol-
ically active overall. This stage may be reﬂected serologi-
cally by a relatively lower increase in COMP levels, and
radiographically by subchondral sclerosis, osteophyte for-
mation and JSN17,18.
Early changes in cartilage metabolism in OA may explain
our ﬁnding that changes in serum COMP levels have differ-
ent associations with incident vs progressive RHOA. Pa-
tients with incident RHOA in this study may have had
more active cartilage turnover, resulting in the association
of a greater percentage increase in serum COMP levels
with incident disease. The progressive RHOA group, on
the other hand, likely had more advanced, less metaboli-
cally active cartilage, which could explain the ﬁnding that
a smaller percentage increase in serum COMP was associ-
ated with less RHOA progression. Patients with progressive
RHOA were also more likely to have a signiﬁcant associa-
tion between the percentage increase in COMP and the on-
set of hip pain by visit 4, possibly as a result of more
advanced hip disease [age-adjusted OR¼ 2.431 (95% CI:
1.28e4.60)].
The strong association of higher quartile increases in
COMP with the development of incident RHOA further sup-
ports the hypothesis that COMP levels increase at a more
rapid rate during periods associated with the development
of incident RHOA. Sharif et al.2 measured serial levels of
serum COMP over 60 months, correlated levels of this bio-
marker with radiographic ﬁndings of knee OA, and reported
serum COMP levels in a patient to be signiﬁcantly in-
creased over any 12e24-month period in which the greatest
radiographic change occurred. These authors also note that
serum COMP levels may differ among subtypes of knee
OA21, but to date, no such distinctions in subtypes of hip
OA have been reported.
Our results differ from previously published reports of
the relationship of serum COMP and RHOA progression.
Conrozier et al.3 followed 48 patients with painful hip
OA over 1 year, and found no change in serum COMP
levels measured 12 months apart, and subsequently, no
correlation between radiographic changes of JSN and
changes in serum COMP levels. In contrast, our study ex-
amined the effect of two measurements of serum COMP
over 6 years in a larger cohort of patients, potentially in-
creasing the ability to link changes in a potential biomarker
to disease progression over time; direct clinical application
of our results is limited for reasons we outline further
below.
We found no statistically signiﬁcant association between
changes in serum NTX levels and the development or
570 R. K. Chaganti et al.: Change in serum measurements of COMPprogression of RHOA. Our group had reported previously
that baseline serum NTX was associated with a modest
risk of incident and progressive RHOA6. Urine NTX has
been evaluated previously by Bettica et al.4 as a risk marker
in progressive knee OA, and was found to be elevated in
patients who later had radiographic progression of knee
OA. This ﬁnding suggests that progression of established
OA reﬂects changes of bone metabolism, rather than carti-
lage turnover. Since urine samples were not available in the
SOF cohort, we could not conﬁrm these ﬁndings. The se-
rum NTX assay has been used to evaluate certain patient
populations with osteoporosis with some success22,23, but
there are few published data to support its reliability as
a measure of OA progression. It may lack the sensitivity
to bone changes occurring in different phases of OA com-
pared to urinary markers of bone turnover.
This study has several strengths. First, the radiographic
methods used to evaluate the incident and progressive
nested groups have been validated extensively. In addition,
the strong associations found between percentage increase
in serum COMP over two timepoints, while limited in imme-
diate clinical applicability, point toward a potential goal of
following the course of this disease. Serial measurements
of a potential biomarker of disease have already been
used in other subspecialties to gauge treatment response
and predict further disease progression; recently, serial
measurements of high sensitivity C-reactive protein
(hsCRP) over several months following an acute ischemic
event have been shown to be helpful in assessing statin
therapy response and in predicting long-term survival in pa-
tients with coronary disease24. Similarly, a strong associa-
tion of serum COMP changes with incident or progressive
RHOA could serve as a potential tool for assessing and pre-
dicting the clinical course of OA in a patient.
Some of the shortcomings of this study have been out-
lined previously6. An additional potential weakness is that
we chose an 8.3-year interval between radiographs, while
serum assays were measured 6 years apart. The discrep-
ancy in measurement times makes it more difﬁcult to deter-
mine with certainty whether the assay level changes or
radiographic changes occurred ﬁrst. This uncertainty, in
turn, limits our ability to correlate serum biomarker changes
with the true onset of RHOA. Additionally, while these re-
sults are statistically signiﬁcant and interesting in generating
hypotheses about the role of COMP and NTX in the devel-
opment of OA, clinical decision-making based on these re-
sults is limited. Signiﬁcant overlap in the absolute values
and percentage increase between the different groups
was observed (see Tables I and II); further investigation
would be required prior to instituting a clinical intervention
based on these results.
In addition, while we controlled for the effect of osteopo-
rosis of the femoral neck on levels of COMP and NTX, we
were not able to control for possible OA at sites other
than the hip, and cannot exclude the possibility that OA in
other sites contributed to the changes in COMP and NTX
values. Also, since this was a racially homogenous cohort
of elderly women, these results cannot be generalized to
other patient groups.
Lastly, since several studies have shown that serum
COMP levels increase with exercise25e27, changes in
a study subject’s activity level may have inﬂuenced the
association we observed between serum COMP levels
and incident and progressive RHOA. Therefore, we re-
analyzed our data and adjusted for two activity-associated
variables: (1) the number of kcal/week expended by the
patient at baseline and (2) the number of hours spentsedentary at baseline and the associations we found were
not changed.
In summary, the change in serum levels of COMP over
two distinct timepoints was found to be a risk factor for pre-
dicting the development of incident or progressive RHOA.
While a percentage increase in COMP over 6 years was
found to be associated with an increased risk of developing
RHOA, a smaller percentage increase in serum COMP was
found to be potentially protective against progression of
RHOA. We found no signiﬁcant relationship between serum
NTX changes and the development of incident or progres-
sive RHOA in our study.Acknowledgements
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